Abby Statler

[Abby Statler @StatlerA16]

Winston was so excited to meet @MikkaelSekeres - he fist pumped 👊🏻 for the first time 😀 ! After all that practicing for #ASH19, I’m pretty confident Winston’s first words will be hematologic malignancy 😂

[Mikkael A. Sekeres MD, MS @MikkaelSekeres]

After giving two talks and one poster at #ASH19 while 8 months pregnant, @StatlerA16 lets me hold another of her flawless presentations!!! What a beautiful boy! 🤗🤗🤗

[Abby Statler @StatlerA16]

Such important work!

[Laura C. Michaelis @lauracmichaelis]

With Enough Patient Support, Cancer Care Disparities Vanish https://t.co/5T5dYHK4CH

[Abby Statler @StatlerA16]

Go @MeganKruseMD 👏

[David Steensma, MD @DavidSteensma]

Covers of all >60 issues @ASHClinicalNews that @MikkaelSekeres has edited - >2200 different articles he’s had to review to ensure subject-verb agreement and that “data” are plural, delete meaningless stuff like “at this point in time”, and change “utilize” to “use” @Jenifer_one_N

[Cleveland Clinic MD @CleClinicMD]

Allison Winter, MD, discusses a collaborative effort focused on the relapse of patients with follicular lymphoma: #ASH19

[Abby Statler @StatlerA16]

Dr. Advani elucidates the prognostic impact of MRD and the outcomes relevant to novel therapies in ALL - excellent educational session 🤓#ASH19 @CleClinicMD #CleClincCancer

[Abby Statler @StatlerA16]

@DeepJagMD harnesses @CIBMTR data to evaluate if adding Ritximab to BEAM conditioning has an impact on transplantation outcomes among DLBCL pts - very interesting talk!
@CleClinicMD #CleClincCancer #ASH19

[Cleveland Clinic MD @CleClinicMD]

.@BldCancerDoc provides tips for utilizing social media to share information and engage with others at #ASH19:

[Lena Winestone, MD MSHP @drlenawine]

Thrilled that work presented at #ASH19 related to SES #disparities in peds #leukemia is receiving media attention. I’m hopeful that w/ increased awareness we can accelerate progress toward a deeper mechanistic understanding & #healthequity. @UCSFChildrens https://t.co/qEaeVcaidJ

[The ASCO Post @ASCOPost]

Mikkael A. Sekeres, MD, on Newly Diagnosed Hematologic Malignancies: Early Trial Findings on Glasdegib Plus Azacitidine https://t.co/7X6PUZU26n #hematology #ASH19 #leusm @MikkaelSekeres @CleClinicMD

[Mikkael A. Sekeres MD, MS @MikkaelSekeres]

Calm, cool, collected, and convincing! Great presentation of Pacritinib trial results from @AaronGerds!

[Abby Statler @StatlerA16]

200mg BID may be the optimal dose of Pacritinib for patients with MF, @AaronGerds giving another fantastic presentation at #ASH2019!

[Abby Statler @StatlerA16]

Looks like @MukherzSudipto is having a blast here presenting his work 🤗 - enjoying the complete Orlando experience!

[Mikkael A. Sekeres MD, MS @MikkaelSekeres]

@MukherzSudipto doing fabulous job discussing risk factors and outcome in @ASH_hematology Guidelines for Older Adults with AML at #ASH19!

[Abby Statler @StatlerA16]

@AaronGerds looking dapper & crushing his oral presentation reporting outcomes from the phase 2 study of Luspatercept in pts with MF associated anemia! 👍 #ASH2019 @CleClinicMD #CleClincCancer Go Dr. Gerds!

[Mikkael A. Sekeres MD, MS @MikkaelSekeres]

In any haiku
Myelodysplastic Syndromes
Fits on just one line

#ASHaiku
#ASH19

[Abby Statler @StatlerA16]

@caitlinsiebe presents her poster that suggests readmissions after consolidation are expected, indicating this might not be an appropriate quality measure for the AML population - interesting findings 👌👍👏 #ASH19 @CleClinicMD #CleClincCancer

[Caitlin Siebenaller, PharmD, BCOP @caitlinsiebe]

When you feel like you have balcony seats for a play at the theater but it’s @MikkaelSekeres presenting on glasdegib + azacitidine in AML and MDS #ASH19. Possibly a great up and coming treatment option for patients!

[Abby Statler @StatlerA16]

@drjainchhavi @CleClinicMD @MikkaelSekeres Thank you!

[Abby Statler @StatlerA16]

Definitely looking 🤰🏼in this photo #36weeks! It is a privilege to discuss our research with the broad community of hematologists attending #ASH19👍
@CleClinicMD @MikkaelSekeres #CleClincCancer

[Rob Dean, MD @drrdean]

Lots of attention at #ASH19 for @StatlerA16 and her work on how restrictive trial eligibility criteria limit access and applicability of new #leukemia treatments, especially for minority populations. #CleClinicCancer @CleClinicMD

[Abby Statler @StatlerA16]

Understanding the therapeutic landscape for MDS, great #ASH2019 educational session chaired by @MikkaelSekeres 👏 @CleClinicMD #CleClincCancer